Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A new revision entry labeled v3.5.5 was added to the record history. The previous revision v3.5.4 was removed.
    Difference
    0.1%
    Check dated 2026-06-05T10:37:33.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The Record History now shows a new revision entry v3.5.4, replacing the previous v3.5.3, reflecting a minor update to the page's history.
    Difference
    0.1%
    Check dated 2026-05-14T23:26:46.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The Record History now shows Revision: v3.5.3, replacing the previous v3.5.2. This indicates the study record has been updated to a newer version.
    Difference
    0.1%
    Check dated 2026-04-30T15:33:44.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Footer revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-16T10:28:09.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Added revision v3.5.0 and removed revision v3.4.3 from the record history.
    Difference
    0.1%
    Check dated 2026-03-25T20:10:46.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    Revision history updated to add v3.4.3 and remove v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-11T15:13:25.000Z thumbnail image

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.